SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Welcome to the POTP board, the DPP-IV company
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (5)7/23/2006 8:09:48 AM
From: rareearth42  Read Replies (1) of 90
 
Wilder and Praveen,

Regarding GENT, in the pediatric study, they were indeed able to predict the development of clinical VOD, but just1 day prior to the complication being recognized clinically. I would emphasize that the pre-defined outcome for the study was mortality, but VOD has other consequences, including renal disease and so forth. I still think treating everyone would give the best outcomes, but they'll have to prove it with a clinical trial.

I think the potential off-label use of defibrotide and additional indications for the treatment/prevention of acute vascular injury will be a bigger market than treatment/prevention of VOD...common conditions like sepsis (although the ships of many biotech companies have foundered on the shoals of sepsis), possibly re-perfusion injury, and rare conditions with vasculopathy as major complications such as scleroderma.

Time will tell!!

RE42
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News